Why the study?
Does angiotensin-receptor blockers induce carcinogenesis or exert anticancer activity in patients receiving treatment for hypertension?
Does angiotensin-receptor blockers induce carcinogenesis or exert anticancer activity in patients receiving treatment for hypertension?
Answers are grounded in this paper and cite their sources.
This review suggests that angiotensin-receptor blockers are more likely to have anticancer properties rather than inducing carcinogenesis, supporting their safety in hypertensive patients.
Recently controversial data emerged regarding the cancer inducing activity of angiotensin-receptor blockers. There may be several reasons which may explain the controversial data published in the scientific literature including wrong trial design or misinterpretation of data. Considering the large number of patients receiving treatment for hypertension, it is essential to have a clear view of the cancer-related safety of these drugs. This paper tries to give an overview on this issue based on data available in the literature. According to our present knowledge, angiotensin-receptor blockers exert more likely anticancer activity rather than carcinogenesis inducing effect. In fact, some oncologic trials point to this direction, because angiotensin-receptor blockers are suggested as co-treatment to chemotherapy in cases of pancreatic, oesophageal and gastric cancers.
No takes yet. Share an insight, caveat, or question.
Telekes et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: